Dudediligence.

Replimune Group, Inc

REPLNASDAQ · Biological Products, (No Diagnostic Substances)
Write an idea

Insiders

Last 12 months

Sales planned on beside the trades reported on , and whether each names a .

Planned ·

$286,595

3 notices · 31,664 sh

Oct 2025 to Oct 2026

Reported ·

$894,699

12 sales · 0 buys

Oct 2025 to Jun 2026

The two figures cover different periods.

3 of 12 reported sales carry the 10b5-1 box. Together they are 0.16% of the shares on issue.

PLANNED · FORM 144Oct 2025 to Oct 2026REPORTED · FORM 4Oct 2025 to Jun 2026N2025DJ2026FMAMJJASO2026-04-02: Christopher Sarchi, Form 1442025-12-09: Kapil Dhingra, Form 1442025-12-02: Sushil Patel, Form 1442025-11-17: Xynos Konstantinos, sold2025-11-17: Sarchi Christopher, sold2025-12-02: Patel Sushil, sold2025-12-09: Dhingra Kapil, sold2026-04-02: Sarchi Christopher, sold2026-05-18: Hill Emily Luisa, sold2026-05-18: Patel Sushil, sold2026-05-18: Astley-Sparke Philip, sold2026-05-18: Sarchi Christopher, sold2026-05-18: Schwendenman Andrew, sold2026-05-18: Xynos Konstantinos, sold2026-06-01: Sarchi Christopher, sold
under a no plan named▼ salesize is dollars

Form 144 notices, newest first

2026-04-02Christopher Sarchi, Chief Commercial Officer$142,450
18,500 shplan 2025-12-15144 ↗
Form 4, 2026-04-06: sold 6,500 at $8.01 Form 4 ↗
2025-12-09Kapil Dhingra, Director$32,842
3,164 shno plan date144 ↗
Form 4, 2025-12-11: sold 3,169 at $10.40 Form 4 ↗
2025-12-02Sushil Patel, Chief Executive Officer$111,303
10,000 shplan 2025-06-02144 ↗
Form 4, 2025-12-04: sold 10,000 at $11.13 Form 4 ↗